2005 – Federal Register Recent Federal Regulation Documents
Results 1 - 50 of 32,488
Proposed Collection; Comment Request
In accordance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 which provides opportunity for public comment on new or revised data collections, the Railroad Retirement Board (RRB) will publish periodic summaries of proposed data collections. Comments are invited on: (a) Whether the proposed information collection is necessary for the proper performance of the functions of the agency, including whether the information has practical utility; (b) the accuracy of the RRB's estimate of the burden of the collection of the information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden related to the collection of information on respondents, including the use of automated collection techniques or other forms of information technology. Title and purpose of information collection: Pension Plan Reports: OMB 3220-0089. Under section 2(b) of the Railroad Retirement Act (RRA), the Railroad Retirement Board (RRB) pays supplemental annuities to qualified RRB employee annuitants. A supplemental annuity, which is computed according to section 3(e) of the RRA, can be paid at age 60 if the employee has at least 30 years of creditable railroad service or at age 65 if the employee has 25-29 years of railroad service. In addition to 25 years of service, a ``current connection'' with the railroad industry is required. Eligibility is further limited to employees who had at least one month of rail service before October 1981 and were awarded regular annuities after June 1966. Further, if an employee's 65th birthday was prior to September 2, 1981, he or she must not have worked in rail service after certain closing dates (generally the last day of the month following the month in which age 65 is attained). Under section 2(h)(2) of the RRA, the amount of the supplemental annuity is reduced if the employees receive monthly pension payments, or lump-sum pension payments, from their former railroad employer, which are based in whole or in part on contributions from that railroad employer. The employees' own contributions to their pension accounts do not cause a reduction. An employer private pension is described in 20 CFR 216.40-216.42. The RRB requires the following information from railroad employers to calculate supplemental annuities: (a) The current status of railroad employer pension plans and whether such employer pension plans cause reductions to the RRB supplemental annuity; (b) the amount of the employer private pension being paid to the employee; (c) whether or not the employer made contributions to the pension; (d) whether or not the employee was cashed out before attaining retirement age under the employer pension plan or received the pension in a lump-sum payment in lieu of monthly pension payments; and (e) whether the employer pension plan continues when the employer status under the RRA changes. The requirement that railroad employers furnish pension information to the RRB is contained in 20 CFR 209.2. The RRB currently utilizes Form(s) G-88p (Employer's Supplemental Pension Report), G-88r (Request for Information About New or Revised Pension Plan), and G-88r.1 (Request for Additional Information about Employer Pension Plan in Case of Change of Employer Status or Termination of Pension Plan), to obtain the necessary information from railroad employers. One response is requested of each respondent. Completion is mandatory. The RRB proposes the addition of several new items to Form G-88p which include ``skip patterns'' intended to allow employers to bypass items when no response is needed. The RRB also proposes editorial and reformatting changes for clarification purposes to several existing items on G-88p. The RRB proposes no changes to Forms G-88r and G-88r.1.
Prospective Grant of Exclusive License: Treatment of Cardiovascular Conditions With Nitrite Therapy
This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the invention embodied in PCT patent applications PCT/US2004/21985 and PCT/US2004/22232, filed July 9, 2004, both entitled ``Use of Nitrite Salts for the Treatment of Cardiovascular Conditions'' [HHS Reference Number: E-254-2003/2-3-PCT- 01], to Hope Medical Enterprises, Inc., dba Hope PharmaceuticalsTM, an Arizona S-Corporation having a principle place of business in Scottsdale, Arizona. The field of use may be limited to the use of nitrite salts for the treatment of cerebral vasospasm following subarachnoid hemorrhage and/or cardiovascular conditions. The United States of America is an assignee of the patent rights in these inventions.
Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Federal Emergency Management Agency (FEMA) has submitted the following information collection to the Office of Management and Budget (OMB) for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. The submission describes the nature of the information collection, the categories of respondents, the estimated burden (i.e., the time, effort and resources used by respondents to respond) and cost, and includes the actual data collection instruments FEMA will use. Title: Federal Assistance for Offsite Radiological Emergency. OMB Number: 1660-0024. Abstract: In accordance with Executive Order 12657, FEMA \1\ will need certain information from the licensee in order to form a decision as to whether or not a condition of ``decline or fail'' exists on the part of State or local governments (44 CFR 352.3-4). This information will be collected by the appropriate FEMA Regional Office or Headquarters. Also in accordance with the Executive Order, when a licensee requests Federal facilities or resources, FEMA will need information from the NRC as to whether the licensee has made maximum use of its resources and the extent to which the licensee has complied with 10 CFR 50.47 (c)(1) and 44 CFR 352.5. This information will be collected by the NRC and will be provided to FEMA through consultation between the two agencies.
Fresh and Chilled Atlantic Salmon From Norway: Final Results of the Full Sunset Review of Antidumping Duty Order
On August 29, 2005, the Department of Commerce (the ``Department'') published a notice of preliminary results of the full sunset review of the antidumping duty order on fresh and chilled Atlantic salmon from Norway (``Salmon from Norway'') pursuant to section 751(c) of the Tariff Act of 1930, as amended (``the Act''). See Fresh and Chilled Atlantic Salmon From Norway: Preliminary Results of the Full Sunset Review of Antidumping Duty Order, 70 FR 51012 (August 29, 2005) (``Preliminary Results''). In those Preliminary Results we provided interested parties an opportunity to comment on our preliminary results. We received a case brief from the Norwegian Seafood Federation and the Norwegian Seafood Association (``respondents'') and a rebuttal brief from Heritage Salmon Company, Inc., and Atlantic Salmon of Maine (the ``domestic interested parties ''). A hearing, requested by respondents, was held on October 26, 2005 at the Department. As a result of this review, the Department finds that revocation of this order would be likely to lead to continuation or recurrence of dumping.
Prospective Grant of Exclusive License: Software for Predicting Molecular Properties and Pathogen Detection
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the invention embodied in E- 169-2000/0 ``Drift Compensation Method for Fingerprint Spectra,'' U.S. Patent Application No. 09/975,530 filed October 10, 2001; E-297-2001/0 ``Methods For Predicting Properties of Molecules,'' U.S. Patent Application No. 10/383,602 filed March 7, 2003; and E-017-2003/0 ``Improved Pattern Recognition Of Whole Cell Mass Spectra Via Separation Of Specific Charge States,'' U.S. Patent Application No. 10/ 863,745 filed June 7, 2004; to Litmus, LLC an Arkansas corporation having its headquarters in Little Rock, Arkansas. The United States of America is the assignee of the patent rights of the above inventions. The contemplated exclusive license may be granted in the field of providing software solutions for pathogen detection and for predicting molecular properties.
Prospective Grant of Exclusive License: Fusion Proteins Comprising Circularly Permuted Ligands
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in United States Patent No. 4,892,827, issued on January 9, 1990, entitled ``Recombinant Pseudomonas Exotoxin: Construction Of An Active Immunotoxin With Low Side Effects'' [E-385-1986/0-US-01]; U.S. Patent No. 5,635,599, issued on June 3, 1997, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-US-01]; PCT Patent Application No. PCT/US95/04468, filed April 6, 1995, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/ 0-PCT-02]; Switzerland Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E- 047-1994/0-CH-03]; Spain Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-ES-04]; United Kingdom Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-GB-05]; Italy Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-IT-06]; Luxembourg Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/ 0-LU-07]; Netherlands Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E- 047-1994/0-NL-09]; German Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-DE-10]; Austria Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-AT-11]; Australia Patent No. 694211, issued on November 5, 1998, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-AU-12]; Belgium Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-BE-13]; Canada Patent No. 2187283, filed on April 6, 1995, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-CA-14]; European Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-EP-15]; France Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/ 0-FR-16]; Ireland Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E- 047-1994/0-IE-17]; Liechtenstein Patent No. 0754192, issued on January 29, 2003, entitled ``Fusion Proteins Comprising Circularly Permuted Ligands'' [E-047-1994/0-LI-18]; and U.S. Patent No. 6,011,002, issued on January 4, 2000, entitled ``Circularly Permutated Ligands And Circularly Permuted Chimeric Molecules'' [E-047-1994/1-US-01] to Protox Therapeutics, Inc., which has offices in Vancouver, British Columbia, Canada. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of Interleukin-4/cytotoxin fusion proteins for the treatment of cancer.
Notice of Receipt of Petition for Decision That Nonconforming 2000-2005 Komet Standard, Classic and Eurolite Trailers Are Eligible for Importation
This document announces receipt by the National Highway Traffic Safety Administration (NHTSA) of a petition for a decision that 2000-2005 Komet Standard, Classic and Eurolite trailers that were not originally manufactured to comply with all applicable Federal motor vehicle safety standards (FMVSS) are eligible for importation into the United States because (1) they are substantially similar to vehicles that were originally manufactured for importation into and sale in the United States and that were certified by their manufacturer as complying with the safety standards, and (2) they are capable of being readily altered to conform to the standards.
Environmental Impact Statements and Regulations; Availability of EPA Comments
EPA does not object to the proposed project. Rating LO.
Application of Gulfstream Air Charter, Inc. for Commuter Air Carrier Authorization
The Department of Transportation is directing all interested persons to show cause why it should not issue an order finding Gulfstream Air Charter, Inc., fit, willing, and able, and awarding it a commuter air carrier authorization to engage in scheduled passenger air transportation as a commuter air carrier.
Meeting of the Ozone Transport Commission
The United States Environmental Protection Agency is announcing the 2006 Special Meeting of the Ozone Transport Commission (OTC). This OTC meeting will explore options available for reducing ground-level ozone precursors in a multi-pollutant context.
Proposed Settlement Under Section 122(h)(1) of the Comprehensive Environmental Response, Compensation and Liability Act, as Amended, 42 U.S.C. 9622(h)(1), P.M. Northwest Site, Swinomish Indian Reservation, Laconnor, WA
In accordance with section 122(i) of the Comprehensive Environmental Response, Compensation and Liability Act, as amended by the Superfund Amendment and Reauthorization Act (``CERCLA''), notice is hereby given of a proposed settlement to resolve claims against P.M. Northwest Inc., Shell Oil Company, and Texaco Inc. The proposed settlement concerns the federal government's past response costs at the PM Northwest Site, located on the Swinomish Indian Reservation, near Laconnor, Washington. The settlement requires the settling parties, PM Northwest Inc., Shell Oil Company, and Texaco Inc., to pay $170,000 to the Hazardous Substance Superfund.
Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Prospective Grant of Exclusive License: Implants for Sustained Ocular Therapeutic Agent Delivery
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the invention embodied in E- 241-1999/0, ``Ocular Therapeutic Agent Delivery Devices And Methods For Making And Using Such Devices;'' U.S. Patent 6,713,081 issued March 30, 2004 and expires March 15, 2021; U.S. Patent Application 10/471,468 filed September 12, 2004; and European Patent Application 02723446.7 filed March 14, 2002; to Lux Biosciences, a Delaware corporation having a principle place of business in Jersey City, New Jersey. The United States of America is the assignee of the patent rights of the above inventions. The contemplated exclusive license may be granted in the field of ocular cyclosporine A delivery for the treatment of graft-versus-host- disease-associated dry eye and Sj[ouml]gren's Syndrome.
Alternate Energy-Related Uses on the Outer Continental Shelf
The MMS is seeking comments on the development of a regulatory program to implement portions of the Energy Policy Act of 2005, Section 388Alternate Energy-Related Uses on the Outer Continental Shelf. Specifically, MMS is seeking comments regarding energy development from sources other than oil and gas and alternate uses of existing facilities.
30-Day Notice of Proposed Information Collection: Form DS-4076, Request for Commodity Jurisdiction (CJ)/U.S. Munitions List (USML) Determination, OMB Control Number 1405-0163
The Department of State has submitted the following information collection request to the Office of Management and Budget (OMB) for approval in accordance with the Paperwork Reduction Act of 1995. Title of Information Collection: Request for Commodity Jurisdiction (CJ)/U.S. Munitions List (USML) Determination. OMB Control Number: 1405-0163. Type of Request: Extension of a Currently Approved Collection. Originating Office: Bureau of Political-Military Affairs, Directorate of Defense Trade Controls, (PM/DDTC). Form Number: DS-4076. Respondents: Business organizations. Estimated Number of Respondents: 300. Estimated Number of Responses: 300. Average Hours per Response: 2 hours. Total Estimated Burden: 600 hours. Frequency: Once per year per respondent. Obligation to Respond: Voluntary.
Bureau of International Security and Nonproliferation; Imposition of Nonproliferation Measures Against Foreign Entities, Including a Ban on U.S. Government Procurement, and Removal of Penalties From One Entity
A determination has been made that nine entities have engaged in activities that require the imposition of measures pursuant to section 3 of the Iran Nonproliferation Act of 2000, which provides for penalties on entities for the transfer to Iran since January 1, 1999, of equipment and technology controlled under multilateral export control lists (Missile Technology Control Regime, Australia Group, Chemical Weapons Convention, Nuclear Suppliers Group, Wassenaar Arrangement) or otherwise having the potential to make a material contribution to the development of weapons of mass destruction (WMD) or cruise or ballistic missile systems. The latter category includes (a) items of the same kind as those on multilateral lists, but falling below the control list parameters, when it is determined that such items have the potential of making a material contribution to WMD or cruise or ballistic missile systems, (b) other items with the potential of making such a material contribution, when added through case-by-case decisions, and (c) items on U.S. national control lists for WMD/missile reasons that are not on multilateral lists. It was also determined that sanctions imposed on an Indian entity, effective September 23, 2004 (69 FR 4845) are rescinded.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Draft Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Regulations Under the Federal Import Milk Act
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Regulations Under the Federal Import Milk Act'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Cosmetic Product Voluntary Reporting Program
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Cosmetic Product Voluntary Reporting Program'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Mammography Quality Standards Act Final Regulations; Modifications and Additions to Policy Guidance Help System #9
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Medical Devices; Humanitarian Use Devices
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Medical Devices; Humanitarian Use Devices'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Information Collection for Part 13, Tribal Reassumption of Jurisdiction Over Child Custody Proceedings
In compliance with the Paperwork Reduction Act of 1995 this notice announces that the Bureau of Indian Affairs is seeking to extend clearance for an information collection request. The information collection, Tribal Reassumption of Jurisdiction Over Child Custody Proceedings, is cleared under OMB Control Number 1076-0112. Interested parties are invited to comment on this collection.
30-Day Notice of Proposed Information Collection: Department of State Acquisition Regulation (DOSAR), OMB Control Number 1405-0050
The Department of State has submitted the following information collection request to the Office of Management and Budget (OMB) for approval in accordance with the Paperwork Reduction Act of 1995. Title of Information Collection: Department of State Acquisition Regulation (DOSAR). OMB Control Number: 1405-0050. Type of Request: Extension of a Currently Approved Collection. Originating Office: Bureau of Administration, Office of the Procurement Executive (A/OPE). Form Number: N/A. Respondents: Any business, other for-profit, individual, not-for-profit, or household organization wishing to receive Department of State contracts. Estimated Number of Respondents: 3,166. Estimated Number of Responses: 3,166. Average Hours Per Response: Varies. Total Estimated Burden: 274,320. Frequency: On occasion. Obligation to Respond: Voluntary.
Implementation of the Highways for LIFE Pilot Program
This document contains the proposed implementation plan of Section 1502 of the Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU) for the Highways for LIFE (HfL) Pilot Program to offer the opportunity for comment into the development of the final implementation document. LIFE is an acronym for ``Long-lasting, Innovative, Fast construction of Efficient and safe pavements and bridges.'' The purpose of the HfL Pilot Program is to accelerate the rate of adoption of innovations and technologies, thereby improving safety and highway quality while reducing congestion caused by construction. This will be accomplished through technology transfer, technology partnerships, information dissemination, incentive funding of up to 20 percent, but not more than $5 million on Federal-aid highway projects (eligible for assistance under Chapter 1 of title 23, United States Code) and HfL program accountability.
Oklahoma Regulatory Program
We, the Office of Surface Mining Reclamation and Enforcement (OSM), are announcing receipt of revisions to a previously proposed amendment to the Oklahoma regulatory program (Oklahoma program) under the Surface Mining Control and Reclamation Act of 1977 (SMCRA or the Act). The revisions Oklahoma proposes concern subsidence control; impoundments; and revegetation success standards. Oklahoma also elected to withdraw its proposed revisions regarding review of decision not to inspect or enforce. Oklahoma intends to revise its program to provide additional safeguards, clarify ambiguities, and improve operational efficiency. This document gives the times and locations that the Oklahoma program and proposed amendment to that program are available for your inspection and the comment period during which you may submit written comments on the revisions to the amendment.
Public Notice
The Centers for Disease Control and Prevention (CDC), National Center for Infectious Disease (NCID), Division of Bacterial and Mycotic Diseases (DBMD) and the National Immunization Program, Epidemiology and Surveillance Division through its component Branches have lead technical responsibility for research, development and evaluation of diagnostic tools for pertussis and application of these to epidemiologic studies of pertussis. CDC uses epidemiologic, laboratory, clinical, and biostatistical sciences to control and prevent vaccine preventable infectious diseases. CDC also conducts applied research in a variety of settings, and translates the findings of this research into public health practice. CDC is seeking to evaluate commercial products, or products in development, for in vitro serological diagnosis of pertussis. Specifically these should include tests to detect anti-pertussis toxin antibodies in infected and vaccinated individuals. The tests should be based on standardized reagents commonly used in the field (such as FDA Reference Serum Standard Lot 3 or equivalents). Products will be evaluated in CDC and collaborating laboratories and if appropriate, may be used in epidemiologic validation studies. Data obtained from this comparative analysis may be used by CDC in making recommendations and decisions for diagnosis of pertussis in the public health setting. Interested organizations that may have candidate products are invited to submit documentation for CDC to assess whether the offered product(s) are at a sufficient stage of development to be included in this comparative analysis. As a minimum, submitted information should be sufficient for CDC to determine the following for each candidate product: (a) Product package insert or detailed instructions for use; (b) Detailed information to determine if the product is calibrated to a recognized standard; and (c) Preliminary data demonstrating suitability for validation studies. Organizations that have products selected by CDC for this comparative analysis will be required to enter into an appropriate agreement prior to the transfer of any material to CDC. Sample agreements may be viewed at the following Web site: https://www.cdc.gov/ od/ads/techtran/forms.htm. All information submitted to CDC will be kept confidential as allowed by relevant federal law, including the Freedom of Information Act (5 U.S.C. 552) and the Trade Secrets Act (18 U.S.C. 1905). Only information submitted within thirty days of publication of this notice will be reviewed to determine if the offered product(s) will be acceptable for possible inclusion in this comparative analysis. Responses are preferred in electronic format and can be e-mailed to the attention of Michael J. Detmer at MDetmer@cdc.gov. Mailed responses can be sent to the following address: Michael J. Detmer, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd., NE., Mail Stop C-09, Atlanta, GA 30333.
Environmental Impact Statement; Woodbury County, IA
The FHWA issued a notice of intent to prepare an Environmental Impact Statement (EIS) for a proposed Interstate 29 corridor study in Sioux City, Iowa from Sioux Gateway Airport/Sergeant Bluff Interchange to the South Dakota State border, published on November 18, 2004, 69 FR 67618. The FHWA is issuing this notice to advise the public of a revision to the study corridor limits. The proposed Interstate 29 study corridor for which an Environmental Impact Statement will be prepared is defined as extending from approximately \1/4\ mile south of the Burlington Northern Santa Fe Railroad Bridge over the Missouri River to Judd Street along the existing Interstate 29 corridor in Sioux City, Iowa.
Airworthiness Directives; Pratt & Whitney JT8D-1, -1A, -1B, -7, -7A, -7B, -9, -9A, -11, -15, -15A, -17, -17A, -17R, -17AR, -209, -217, -217A, -217C, and -219 Turbofan Engines
The FAA proposes to supersede an existing airworthiness directive (AD) for Pratt & Whitney (PW) JT8D-209, -217, -217A, -217C, and -219 turbofan engines. That AD currently requires initial and repetitive visual inspections for fretting and fluorescent magnetic particle inspections (FMPI) for cracking in the area of the tierod holes on 8th stage high pressure compressor (HPC) front hubs (from here on, referred to as HPC front hubs) that have operated at any time with PWA 110-21 coating. This proposed AD would require either replacing HPC front hubs and HPC disks that have operated at any time with PWA 110-21 coating and that operated in certain engine models, or, visually inspecting and FMPI for cracking of those parts and replating them if they pass inspection. This proposed AD would also require adding JT8D- 1, -1A, -1B, -7, -7A, -7B, -9, -9A, -11, -15, -15A, -17, 17A, 17R, and 17AR engines to the applicability. This proposed AD results from an investigation by PW, which concluded that any HPC front hub or HPC disk coated with PWA 110-21 that ever operated on JT8D-15, -15A, -17, -17A, -17R, -17AR, -209, -217, -217A, -217C, and -219 turbofan engines, could crack before reaching their published life limit. We are proposing this AD to prevent a rupture of an HPC front hub or an HPC disk that could result in an uncontained engine failure and damage to the airplane.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.